Altered antibody titers in patients with neuromuscular diseases after high-dose intravenous immunoglobulin therapy
We investigated the changes in antibody titers after intravenous immunoglobulin (IVIg) administration in patients with neuromuscular diseases. Among patients who received IVIg from April 1, 2020, to August 31, 2022, we retrospectively evaluated 15 patients with antibody measurements before and after IVIg administration for any rise in the following antibody levels and examined the data for subsequent changes of false positive results to negative ones. The levels of anti SS-A, anti-thyroglobulin, anti-thyroid peroxidase, anti-glutamic acid decarboxylase, HBs, and HBc antibodies transiently increased after IVIg administration and showed false-positive results. However, levels of rheumatoid factor and anti-nuclear and antineutrophil cytoplasmic antibodies were not elevated. The false-positive results became negative after 3 months. Here, we report on the changes in antibody levels before and after IVIg administration and note that levels of hepatitis B virus-related antibodies and various autoantibodies transiently rise after IVIg administration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Rinsho shinkeigaku = Clinical neurology - 64(2024), 3 vom: 22. März, Seite 157-162 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Shiraishi, Wataru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9009-79-4 |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5692/clinicalneurol.cn-001895 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368594017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368594017 | ||
| 003 | DE-627 | ||
| 005 | 20240326235449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.5692/clinicalneurol.cn-001895 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368594017 | ||
| 035 | |a (NLM)38369330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Shiraishi, Wataru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Altered antibody titers in patients with neuromuscular diseases after high-dose intravenous immunoglobulin therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We investigated the changes in antibody titers after intravenous immunoglobulin (IVIg) administration in patients with neuromuscular diseases. Among patients who received IVIg from April 1, 2020, to August 31, 2022, we retrospectively evaluated 15 patients with antibody measurements before and after IVIg administration for any rise in the following antibody levels and examined the data for subsequent changes of false positive results to negative ones. The levels of anti SS-A, anti-thyroglobulin, anti-thyroid peroxidase, anti-glutamic acid decarboxylase, HBs, and HBc antibodies transiently increased after IVIg administration and showed false-positive results. However, levels of rheumatoid factor and anti-nuclear and antineutrophil cytoplasmic antibodies were not elevated. The false-positive results became negative after 3 months. Here, we report on the changes in antibody levels before and after IVIg administration and note that levels of hepatitis B virus-related antibodies and various autoantibodies transiently rise after IVIg administration | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a autoantibody | |
| 650 | 4 | |a false positive | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a intravenous immunoglobulin | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Rheumatoid Factor |2 NLM | |
| 650 | 7 | |a 9009-79-4 |2 NLM | |
| 650 | 7 | |a Hepatitis B Antibodies |2 NLM | |
| 700 | 1 | |a Inamori, Yukiko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuyoshi, Ayano |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Tetsuya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho shinkeigaku = Clinical neurology |d 1972 |g 64(2024), 3 vom: 22. März, Seite 157-162 |w (DE-627)NLM000226874 |x 1882-0654 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g number:3 |g day:22 |g month:03 |g pages:157-162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5692/clinicalneurol.cn-001895 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |e 3 |b 22 |c 03 |h 157-162 | ||